$29.52
+0.65
(+2.25%)▲
1.86%
Downside
Day's Volatility :3.63%
Upside
1.8%
54.03%
Downside
52 Weeks Volatility :74.43%
Upside
44.39%
Period | Arvinas Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -8.8% | 6.5% | 0.0% |
6 Months | -19.85% | 7.1% | 0.0% |
1 Year | 32.5% | 9.8% | 0.0% |
3 Years | -68.89% | 14.2% | -20.2% |
Market Capitalization | 2.0B |
Book Value | $8.93 |
Earnings Per Share (EPS) | -6.05 |
Wall Street Target Price | 68.44 |
Profit Margin | 0.0% |
Operating Margin TTM | -329.25% |
Return On Assets TTM | -20.78% |
Return On Equity TTM | -63.32% |
Revenue TTM | 71.3M |
Revenue Per Share TTM | 1.19 |
Quarterly Revenue Growth YOY | -22.2% |
Gross Profit TTM | 131.4M |
EBITDA | -392.3M |
Diluted Eps TTM | -6.05 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -4.34 |
EPS Estimate Next Year | -4.58 |
EPS Estimate Current Quarter | -1.41 |
EPS Estimate Next Quarter | -1.21 |
What analysts predicted
Upside of 131.84%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 14.3M | ↑ 89.0% |
Net Income | -41.5M | ↑ 72.48% |
Net Profit Margin | -289.59% | ↑ 27.73% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 43.0M | ↑ 200.03% |
Net Income | -62.1M | ↑ 49.79% |
Net Profit Margin | -144.57% | ↑ 145.02% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 21.8M | ↓ 49.27% |
Net Income | -111.8M | ↑ 79.92% |
Net Profit Margin | -512.74% | ↓ 368.17% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 46.7M | ↑ 114.2% |
Net Income | -183.2M | ↑ 63.88% |
Net Profit Margin | -392.29% | ↑ 120.45% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 131.4M | ↑ 181.37% |
Net Income | -271.9M | ↑ 48.42% |
Net Profit Margin | -206.93% | ↑ 185.36% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 78.5M | ↓ 40.26% |
Net Income | -367.3M | ↑ 35.09% |
Net Profit Margin | -467.9% | ↓ 260.97% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 38.0M | ↑ 25.41% |
Net Income | -79.9M | ↑ 20.69% |
Net Profit Margin | -210.26% | ↑ 8.22% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 32.5M | ↓ 14.47% |
Net Income | -80.8M | ↑ 1.13% |
Net Profit Margin | -248.62% | ↓ 38.36% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 54.5M | ↑ 67.69% |
Net Income | -66.6M | ↓ 17.57% |
Net Profit Margin | -122.2% | ↑ 126.42% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 34.6M | ↓ 36.51% |
Net Income | -64.0M | ↓ 3.9% |
Net Profit Margin | -184.97% | ↓ 62.77% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | -43.1M | ↓ 224.57% |
Net Income | -154.8M | ↑ 141.88% |
Net Profit Margin | 359.16% | ↑ 544.13% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 25.3M | ↓ 158.7% |
Net Income | -69.4M | ↓ 55.17% |
Net Profit Margin | -274.31% | ↓ 633.47% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 199.3M | ↑ 198.11% |
Total Liabilities | 62.6M | ↓ 5.99% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 301.6M | ↑ 51.36% |
Total Liabilities | 75.0M | ↑ 19.71% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 717.4M | ↑ 137.82% |
Total Liabilities | 75.1M | ↑ 0.21% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.6B | ↑ 120.47% |
Total Liabilities | 799.9M | ↑ 964.96% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.3B | ↓ 19.78% |
Total Liabilities | 703.9M | ↓ 12.0% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 1.3B | ↑ 2.82% |
Total Liabilities | 644.6M | ↓ 8.42% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.3B | ↓ 4.94% |
Total Liabilities | 703.9M | ↓ 1.32% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.2B | ↓ 7.33% |
Total Liabilities | 664.8M | ↓ 5.55% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.1B | ↓ 7.85% |
Total Liabilities | 619.9M | ↓ 6.75% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.1B | ↓ 2.33% |
Total Liabilities | 601.1M | ↓ 3.03% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.3B | ↑ 23.27% |
Total Liabilities | 644.6M | ↑ 7.24% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 1.2B | ↓ 7.05% |
Total Liabilities | 602.9M | ↓ 6.47% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -16.1M | ↓ 415.22% |
Investing Cash Flow | -179.7M | ↓ 960.79% |
Financing Cash Flow | 168.1M | ↓ 104250.7% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -40.6M | ↑ 152.06% |
Investing Cash Flow | -93.1M | ↓ 48.18% |
Financing Cash Flow | 139.7M | ↓ 16.85% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -89.8M | ↑ 120.93% |
Investing Cash Flow | 164.3M | ↓ 276.43% |
Financing Cash Flow | 504.7M | ↑ 261.14% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 559.4M | ↓ 723.24% |
Investing Cash Flow | -1.3B | ↓ 899.76% |
Financing Cash Flow | 278.6M | ↓ 44.8% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -273.5M | ↓ 148.89% |
Investing Cash Flow | 242.8M | ↓ 118.48% |
Financing Cash Flow | 4.7M | ↓ 98.31% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -71.2M | ↑ 6.91% |
Investing Cash Flow | 19.4M | ↓ 81.66% |
Financing Cash Flow | 500.0K | ↓ 58.33% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -91.2M | ↑ 28.09% |
Investing Cash Flow | 138.6M | ↑ 614.43% |
Financing Cash Flow | 1.5M | ↑ 200.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -88.7M | ↓ 2.74% |
Investing Cash Flow | 48.6M | ↓ 64.94% |
Financing Cash Flow | 500.0K | ↓ 66.67% |
Sell
Neutral
Buy
Arvinas Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Arvinas Inc | 14.11% | -19.85% | 32.5% | -68.89% | 6.92% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Arvinas Inc | NA | NA | NA | -4.34 | -0.63 | -0.21 | NA | 8.93 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Arvinas Inc | Buy | $2.0B | 6.92% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Arvinas Inc
Revenue is up for the last 2 quarters, -43.1M → 25.3M (in $), with an average increase of 270.4% per quarter
Netprofit is up for the last 2 quarters, -154.8M → -69.4M (in $), with an average increase of 123.1% per quarter
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 29.1%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 255.4%
EcoR1 Capital, LLC
Vanguard Group Inc
BlackRock Inc
T. Rowe Price Associates, Inc.
RTW INVESTMENTS, LLC
Avidity Partners Management LP
Arvinas Inc’s price-to-earnings ratio stands at None
Read Morearvinas is a pharmaceutical company focused on developing new small molecules ‒ known as protacs (proteolysis targeting chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. based on innovative research conducted at yale university by dr. craig crews, founder and chief scientific advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. the proprietary protac-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. this greatly expands the ability to create drugs for many new, previously unapproachable targets. for more information, visit www.arvinas.com.
Organization | Arvinas Inc |
Employees | 445 |
CEO | Dr. John G. Houston Ph.D. |
Industry | Health Technology |
Outfront Media Inc.
$29.52
+2.25%
Blackrock Short Duration Bond Etf
$29.52
+2.25%
Moog Inc
$29.52
+2.25%
Edgio Inc.
$29.52
+2.25%
Invesco S&p 500 Momentum Etf
$29.52
+2.25%
Silicon Laboratories Inc
$29.52
+2.25%
Helmerich & Payne, Inc.
$29.52
+2.25%
Crane Nxt Co
$29.52
+2.25%
Liberty Global Plc - Class C Shares
$29.52
+2.25%